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This data article contains insights into the methodology used for
the analysis of three exonic mutations altering the splicing of the
IDS gene: c.241C4T, c.257C4T and c.1122C4T.
We have performed splicing assays for the wild-type and
mutant minigenes corresponding to these substitutions. In addi-
tion, bioinformatic predictions of splicing regulatory sequence
elements as well as RNA interference and overexpression experi-
ments were conducted.
The interpretation of these data and further extensive experi-
ments into the analysis of these three mutations and also into thevier Inc. This is an open access article under the CC BY license
/j.bbadis.2015.09.011
.pt (L. Matos), vania.goncalves@insa.min-saude.pt (V. Gonçalves),
o.laranjeira@chp.min-saude.pt (F. Laranjeira),
.min-saude.pt (P. Jordan), lruiz@cbm.csic.es (L.R. Desviat),
in-saude.pt (S. Alves).
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L. Matos et al. / Data in Brief 5 (2015) 810–817 811methodology applied to correct one of them can be found in
“Functional analysis of splicing mutations in the IDS gene and the
use of antisense oligonucleotides to exploit an alternative therapy
for MPS II” Matos et al. (2015) [1].
& 2015 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Biology
ore speciﬁc sub-
ject areaMolecular geneticsype of data Text, ﬁgures, tables and graphs
ow data was
acquiredAgarose gel images, quantitative real-time PCR, western blotting, in silico
analyses (Splicing rainbow and ESEﬁnder 3.0 software)ata format Raw, analyzed
xperimental
factorsCell lines (Hep3B and COS-7) treated with different minigenesxperimental
featuresWild-type and mutant minigenes were transfected in COS-7 and Hep3B cell lines
and the splicing patterns analysed by RT-PCR. SRSF1 (formerly ASF/SF2) siRNAs
and plasmids coding for SRSF2 (formerly SC35), hnRNP E1 and hnRNP E2 spli-
cing factors were transfected in Hep3B cells and the experiments analysed by
quantitative real-time PCR and/or Western blotting. In silico predictions were
done using Splicing rainbow and ESEﬁnder 3.0 software.ata source
locationINSA, Porto, Portugalata accessibility All data provided within the articleValue of the data
 Data show the methodology for the analysis of the effect of three exonic mutations on splicing.
 Experimental and in silico data are presented.
 The data may be valuable for future studies addressing the impact of mutations in splicing.1. Data, materials and methods
The IDS gene encodes the lysosomal hydrolase iduronate-2-sulphatase, the enzyme that is deﬁ-
cient in the X-Linked Lysosomal Storage Disease; Mucopolysaccharidosis type II [2].
Here, we performed cell-based functional splicing assays to deeper analyze the effects of two
splicing mutations located in exon 3 of IDS, c.241C4T and c.257C4T and one in exon 8, c.1122C4T
that were also studied in Matos et al. [1]. The pathogenic effects of these mutations are shown in
Fig. 1. Also, all the data relative to oligonucleotides sequences used in the work are depicted in
Table 1. Furthermore, to identify the putative SR proteins involved in the splicing regulation we have
undertaken bioinformatic predictions of splicing regulatory elements (SREs) in the IDS exon 3 (where
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ware (Fig. 2 and 3). Finally, we have conducted RNAi and overexpression experiments that were
quantiﬁed by Real time PCR and Western blot (Tables 1, 2 and Fig. 4).
1.1. Oligonucleotides sequences
See Table 1.
1.2. Minigenes construction and in vitro functional splicing analysis
For the in vitro splicing analysis of the variants c.257C4T and c.241C4T in IDS exon 3, the
respective regions of patient and healthy control genomic DNA were ampliﬁed and cloned into
pcDNA3.1-myc, a modiﬁed plasmid vector (Invitrogen, Carlsbad, USA) (Table 1 and Fig. 1A).
Also, to functionally investigate the splicing defects caused by c.1122C4T in exon 8, wild-type
(WT) and mutant minigenes were constructed in vector pSPL3 (Exon Trapping System, Life Tech-
nologies, Gibco, NY, USA) (Table 1 and Fig. 1C). To perform the functional splicing assays, Hep3B and
COS-7 cell lines (4105) were grown in 6-well plates and transfected with WT or mutant minigenes
(2 μg) using 4 μl of Lipofectamine 2000 (Invitrogen, Carlsbad, USA). At 24 h post-transfection, total
RNA was extracted from the cells and used as a template for cDNA synthesis. RT-PCR was then per-
formed using vector speciﬁc primers (Table 1) and the ampliﬁed products were separated by agarose
gel electrophoresis (Fig. 1B and D).
1.3. Bioinformatic analysis of SREs in IDS exon 3;
In silico predictions for alterations in exonic splicing enhancer or silencer sequences (splicing
regulatory elements – SREs) in the presence or absence of c.257C4T and c.241C4T mutations in IDS
exon 3 were performed using ESEﬁnder 3.0 (http://rulai.cshl.edu/cgi-bin/tools/ESE3/eseﬁnder.cgi?
process¼home) [3,4], and Splicing Rainbow (http://www.ebi.ac.uk/asd) [5] software (Figs. 2 and 3).
1.4. Quantitative Real time PCR and Western blot assays to conﬁrm overexpression and depletion of
splicing factors
To conﬁrm the predicted changes in the splicing factors SRSF2 (formerly SC35), hnRNP E1 and
hnRNP E2, overexpression studies were performed using plasmids coding for them which were co-
transfected in Hep3B cells with WT or mutant c.257C4T minigenes. All transfections were performed
using Lipofectamine 2000 reagent. At 48 h post-cotransfection, the cells were harvested and the
transcript pattern analyzed by RT-PCR. Depletion studies were also performed to verify the predicted
changes for the SRSF1 (formerly ASF/SF2) splicing factor. Hep3B cells were ﬁrstly transfected with
siRNAs targeting the mRNA of SRSF1 and luciferase (control) and 24 h later transfected with the WTFig. 1. Splicing assays for the wild-type (WT) and mutant minigenes corresponding to the IDS nucleotide changes c.257C4T
and c.241C4T in exon 3, and c.1122C4T in exon 8. (A, C) Diagrams of the reporter minigenes used in the functional splicing
experiments. Normal and mutated genomic IDS sequences were cloned into the pcDNA3.1-myc or pSPL3 vectors to generate
the indicated minigenes. Exons are shown by boxes and introns by straight lines. For all exonic alterations, the WT and mutant
regions are shown and the speciﬁc changes marked by an arrow. (B, D) Wild-type and mutant minigenes were transfected into
COS-7 and Hep3B cells and the splicing pattern analyzed by RT-PCR using the indicated vector-speciﬁc primers (arrows in
diagrams A and C). Minigene expression of the splicing mutations in exon 3 (c.257C4T and c.241C4T) revealed two tran-
scripts, a predominant one with exon 2 and a mutated exon 3, and a minor transcript of smaller size in which the ﬁrst 44
nucleotides of exon 3 were missing. The WT minigene produced a single transcript of normal size (B). For the synonymous
c.1122C4T change in exon 8, the mutant minigene showed a single transcript lacking the last 60bp of exon 8. The WT construct
produced two bands, one corresponding to the transcript with exon 8 inserted, the other to a transcript resulting from an
expected splicing event between the vector splice sites (D). A diagram of the bands characterized by sequence analysis is also
provided. NC – negative control; V – vector sequence.
Fig. 2. Bioinformatic predictions of splicing regulatory sequence elements in IDS exon 3 using the Splicing Rainbow software.
For the mutation c.241C4T, no alterations were predicted. In the presence of the c.257C4T mutation, no hnRNP E1 or hnRNP
E2 silencer motif is recognized (A) and a SRSF1 (formerly ASF/SF2) motif is created (B). The mutated nucleotide is marked in
red.
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siRNAs are described in Table 1.
To conﬁrm the overexpression of SRSF2, hnRNP E1 and hnRNP E2 as also the depletion of SRSF1 in
whole cell lysates, quantitative Real-Time PCR (qRT-PCR) assays were performed. Relative levels of
gene expression were analyzed using Taqman Universal PCR Master Mix 1x (Applied Biosystems) and
the Taqman Gene Expression Kit (which includes primers and probes for each speciﬁc splicing factor
gene – Table 1). The relative mRNA levels of target genes were calculated using standard curves
(values ranging from 0.05 ng to 50 ng of RNA converted into cDNA). A standard curve was constructed
for each target gene relating Ct values to log RNA quantities. The normalization of expression was
given by the ratio between the RNA concentrations of each target gene and the endogenous geneFig. 3. Bioinformatic predictions of splicing regulatory sequence elements in IDS exon 3 using the ESEﬁnder 3.0 software. For
the mutation c.241C4T, no alterations were predicted. In the presence of the c.257C4T mutation, a putative binding motif for
SRSF1 (formerly ASF/SF2) is slightly altered (red square) and a binding motif for SRSF2 (formerly SC35) is eliminated (blue
square).
Table 1
Description of the different sequences used in the work: primers for PCR ampliﬁcationsa; small interfering RNA's for silencing
of speciﬁc genes; probes used for real-time quantitative PCR; antisense oligonucleotide sequences.
Oligonucleotide Sequence (50 to 30)
Cloning fragments
Intron 1 BamHI F ATATATGGATCCTCCAGCCTTGGGCCTCTT
Intron 3 XhoI R ATATATCTCGAGGAATGCTGGATTCAGACA
Intron 7 IDS F TATCTCGAGGAACCGCCACAGAGTCCT
Intron 8 IDS R TATGGATCCGCACCTGTTCCTTTGTCC
RT-PCR fragments
Exon 2 IDS F TCATCATCGTGGATGACCTG
Exon 3 IDS R AAAGACTTTTCCCACCGACA
Exon 7 IDS F GGAAAATCCGCCAGAGCTAC
Exon 9 IDS R GATCTCCACCTTGGGAATCA
Plasmid vector primers
K-myc-Bam F TACCGCCACCATGGAGCAGAA
pfGHr1 R TTTATTAGGAAAGGACAGTGGG
SD6 F TCTGAGTCACCTGGACAACC
SA2 R ATCTCAGTGGTATTTGTGAGC
Small interfering RNA's
siSRSF1(formerly ASF/SF2)-a AGAAGAUAUGACCUAUGCA
siSRSF1 (formerly ASF/SF2)-b GCAGGUGAUGUAUGUUAUG
siLUC (control) CGUACGCGGAAUACUUCGA
TaqMan gene expression assays
SRSF2 (formerly SC35) Hs 00427515_g1 (Applied Biosystems)
SRSF1 (formerly ASF/SF2) Hs 00199471_m1 (Applied Biosystems)
hnRNP E1 (PCBP1) Hs 00362410_s1 (Applied Biosystems)
hnRNP E2 (PCBP2) Hs 01590472_mH (Applied Biosystems)
Antisense Oligonucleotides
AMO 1 IDS GTAAGGGAAAAGCTTCTCACCTGCC
AMO 2 IDS TTCTCACCTGCCTCCGGAAGTGAAG
AMO 3 IDS AAAGCTTCTCACCTGCCTCCGGAAG
AMO Standard CCTCTTACCTCAGTTACAATTTATA
LNA IDS AAAGCTTCTCACCTGCCTCC
a Primers were designed according to the sequence described in the ENSEMBL database (www.ensembl.org;
ENSG00000010404). F – Forward; R – Reverse.
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target and control samples (Table 2).
The depletion of the SRSF1 splicing factor was also conﬁrmed through Western blotting analysis.
The immunodetection was carried out using the primary antibodies mouse anti-SF2/ASF clone 96
from Zymed (San Francisco, CA) and anti-α-tubulin from Sigma-Aldrich (Switzerland) (Fig. 4).Acknowledgments
LM was supported by a Grant (SFRH/BD/64592/2009) from the Fundação para a Ciência e Tec-
nologia IP (FCT)/POPH/FSE, Portugal.
Fig. 4. Western blot analysis of the degree of depletion achieved after transfection of siRNAs for luciferase (control) and SRSF1
(formerly ASF/SF2) plus the WT exon 3 or c.257C4T mutation minigenes. The immunoblot shows the suppression of the
endogenous SRSF1 when silencing was performed using 200 mM of the siRNA pool. α-tubulin was used as a loading control.
Table 2
Quantiﬁcation and normalization ratio for PGK1, SRSF2 (formerly SC35), hnRNP E1, hnRNP E2 and SRSF1 (formerly ASF/SF2)
expression levels obtained through quantitative real-time PCR. Calculations of relative amounts of each target and endogenous
reference RNA were determined using the appropriate standard curve.
Sample Amount of PGK1
RNA (ng)
Amount of trans-acting
factor RNA (ng)
Normalized amount
of trans-acting factor
RNA (ng)
Ratio
SRSF2 overexpression
WT ex3 minigeneþEmpty vector 1.2 1.4 1.2 1
c.257C4T mutþEmpty vector 1.3 1.8 1.3 1
WT ex3 minigeneþSRSF2 1.5 14.6 9.7 8.1
c.257C4T mutþSRSF2 1.2 17.9 14.6 11.2
hnRNP E1 overexpression
WT ex3 minigeneþEmpty vector 0.45 0.2 0.45 1
c.257C4T mutþEmpty vector 0.9 0.95 1.06 1
WT ex3 minigeneþhnRNP E1 0.68 6.34 9.32 20.71
c.257C4T mutþhnRNP E1 0.46 8.73 18.98 17.91
hnRNP E2 overexpression
WT ex3 minigeneþEmpty vector 0.76 0.22 0.29 1
c.257C4T mutþEmpty vector 1.03 0.78 0.76 1
WT ex3 minigeneþhnRNP E2 0.96 2.04 2.13 7.34
c.257C4T mutþhnRNP E2 0.76 3.89 5.12 6.74
SRSF1 silencing
siLUCþWT ex3 minigene 0.58 0.55 0.95 1
siLUCþc.257C4T mut 0.99 0.77 0.78 1
siSRSF1þWT ex3 minigene 1.16 0.15 0.13 0.14
siSRSF1þc.257C4T mut 0.56 0.08 0.14 0.18
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